Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data
/in Breast Cancer, Hyperthermia, International Publications /von 2015-04-01 / Breast Care (Basel) 2015 Apr;10(2):109-16Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy
/in Esophageal Carcinoma, Hyperthermia, International Publications /von 2015-04-01 / Anticancer Res. 2015 Apr;35(4):2299-303Concomitant trimodality therapy of re-irradiation, chemotherapy and regional hyperthermia for a pretreated inoperable sarcoma recurrence
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2015-03-01 / Tumori 2015 Mar-Apr;101(2):e54-6PET response criteria in solid tumors predicts progression-free survival and time to local or distant progression after chemotherapy with regional hyperthermia for soft-tissue sarcoma
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2015-02-26 / J. Nucl. Med. 2015 Apr;56(4):530-7Hyperthermia Sensitizes Glioma Stem-like Cells to Radiation by Inhibiting AKT Signaling
/in Glioblastoma, Hyperthermia, International Publications /von 2015-02-20 / Cancer Res. 2015 Apr;75(8):1760-9Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion
/in Hyperthermia, International Publications /von 2015-02-12 / Cell Death Dis 2015 Feb;6:e1633Local tumour hyperthermia as immunotherapy for metastatic cancer
/in Hyperthermia, International Publications /von 2014-12-01 / Int J Hyperthermia 2014 Dec;30(8):531-9Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2014-10-21 / J. Cell. Mol. Med. 2015 Feb;19(2):340-50Inhibition of cell proliferation by mild hyperthermia at 43˚C with Paris Saponin I in the lung adenocarcinoma cell line PC-9
/in Hyperthermia, International Publications, NSCLC /von 2014-10-15 / Mol Med Rep 2015 Jan;11(1):327-32
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de